Imdad et al. BMC Public Health 2011, 11(Suppl 3):S18 http://www.biomedcentral.com/1471-2458/11/S3/S18 Page 4 of 13 Total searches Pubmed: 1346 Cochrane: 1 WHO regional data bases=105 Additional records identified through other sources (n = 7) Maternal outcomes Maternal mortality (n=1) Eclampsia (n=1) Records after duplicates removed (n = 1402) Records screened (n = 1402) Full text articles assessed for eligibility (n = 29) Studies included in Meta analysis: (n = 10) Neonatal mortality (n=1) Sever pre eclampsia (n=3) Records excluded (n = 1372) Full text articles excluded (n = 19) Neonatal outcomes Preterm birth (n=5) Small for gestational age (n=2) Low birth weight (n=3) Preeclampsia (n=10) Gestational hypertension (n=6) Figure 1 Flow diagram for identification of studies evaluating calcium supplementation during pregnancy for prevention of maternal hypertensive disorders. The overall quality grade for this outcome was that of ‘low’ level due to very low number of events. In the same study, a cumulative outcome for severe maternal morbidity/mortality was also reported. It included all the severe morbidities related to maternal hypertensive disorders that can lead to maternal death [44]. These morbidities include: admission to intensive or special care unit, eclampsia, severe pre-eclampsia, placental abruption, HELLP (hemolysis, elevated liver enzyme and low platelet count) syndrome, renal failure and maternal death. Maternal calcium supplementation during preg- nancy showed a significant reduction in the intervention compared to control (RR 0.80; 95 % CI 0.70-0.91). The overall quality grade for this outcome was that of ‘mod- erate’ level. Eclampsia One large trial [44] reported outcome on eclampsia. The trials reported 17 cases of eclampsia in 4151 participants